文献速递炎症性肠病消化道肿瘤与早癌消化内镜

染料染色内镜与标准及高清白光内镜在结肠癌风险增高的炎症性肠病患者中的比较:一项Meta分析

Meta-analysis of dye-based chromoendoscopy compared with standard- and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer.
PubMed 文献 · Gastrointest Endosc · 2019-04-19

该系统评价检索PubMed、EMBASE和Web of Science至2018年4月,纳入10项研究(6项随机对照试验)。随机对照试验中,染色内镜识别异型增生患者比例17%(84/494) vs 白光内镜11%(55/496),RR 1.50(95%CI 1.08-2.10);染色内镜仅优于标准白光内镜(RR 2.12),不优于高清白光内镜(RR 1.36,95%CI 0.84-2.18)。非随机对照试验中染色内镜优势更明显(RR 3.41)。证据质量分别为中等和极低。

要点

  • 随机对照试验中染色内镜较白光内镜提高异型增生检出(RR 1.50,95%CI 1.08-2.10)。
  • 随机对照试验中染色内镜优于标准白光内镜(RR 2.12),但不优于高清白光内镜(RR 1.36,95%CI 0.84-2.18)。
  • 非随机对照试验显示染色内镜优于标准及高清白光内镜,但证据质量极低。

核心结论

  • 非随机对照试验显示染色内镜优于标准和高清白光的优势,而随机对照试验仅显示染色内镜较标准白光内镜有小幅优势,较 HDWLE 无优势。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、EMBASE和Web of Science(2018年4月),纳入10项研究,其中6项为随机对照试验(3项比较标准白光内镜,3项比较高清白光内镜)。

主要发现

  • 随机对照试验中,染色内镜组17%(84/494)患者检出异型增生,白光内镜组11%(55/496),RR 1.50(95%CI 1.08-2.10)。
  • 随机对照试验中,染色内镜(n=249)识别异型增生优于标准白光内镜(n=248)(RR 2.12;95%CI 1.15-3.91),但不优于高清白光内镜(n=248)(RR 1.36;95%CI 0.84-2.18)。
  • 非随机对照试验中,染色内镜组16%(114/698)患者检出异型增生,白光内镜组6%(62/1069),RR 3.41(95%CI 2.13-5.47)。
  • 非随机对照试验中,染色内镜(n=58)识别异型增生优于标准白光内镜(n=141)(RR 3.52;95%CI 1.38-8.99),染色内镜(n=113)也优于高清白光内镜(n=257)(RR 3.15;95%CI 1.62-6.13)。

关键数值与推荐

  • 随机对照试验证据质量评为中等。
  • 非随机对照试验证据质量评为极低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with ulcerative colitis have an increased risk of colorectal cancer. We sought to assess the comparative efficacy of standard white-light endoscopy (SDWLE) or high-definition white-light endoscopy (HDWLE) versus dye-based chromoendoscopy through a meta-analysis and rate the quality of evidence using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) system. METHODS: A systematic review of the literature in PubMed, EMBASE, and Web of Science was performed in April 2018. The primary outcome was the number of patients in whom dysplasia was identified using a per patient analysis in randomized controlled trials (RCT) and analyzed separately for non-RCTs. Analysis was performed using RevMan 5.3 reporting random-effects risk ratios. RESULTS: Of the 27,904 studies identified, 10 studies were included 6 of which were RCTs (3 SDWLE and 3 HDWLE). Seventeen percent (84/494) of patients were noted to have dysplasia using chromoendoscopy compared with 11% (55/496) with white-light endoscopy (relative risk [RR] 1.50; 95% confidence interval [CI], 1.08-2.10). When analyzed separately, chromoendoscopy (n = 249) was more effective at identifying dysplasia than SDWLE (n = 248) (RR, 2.12; 95% CI, 1.15-3.91), but chromoendoscopy (n = 245) was not more effective compared with HDWLE (n = 248) (RR, 1.36; 95% CI, 0.84-2.18). The quality of evidence was moderate. In non-RCTs, dysplasia was identified in 16% (114/698) of patients with chromoendoscopy compared with 6% (62/1069) with white-light endoscopy (RR, 3.41; 95% CI, 2.13-5.47). Chromoendoscopy (n = 58) was more effective than SDWLE (n = 141) for identification of dysplasia (RR, 3.52; 95% CI, 1.38-8.99), and chromoendoscopy (n = 113) was also more effective than HDWLE (n = 257) (RR, 3.15; 95% CI, 1.62-6.13). The quality of the evidence was very low. CONCLUSION: Based on this meta-analysis, non-RCTs demonstrate a benefit of chromoendoscopy over SDWLE and HDWLE, whereas RCTs only show a small benefit of chromoendoscopy over SDWLE, but not over HDWLE.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Feuerstein JD, Rakowsky S, Sattler L, et al. Meta-analysis of dye-based chromoendoscopy compared with standard- and high-definition white-light endoscopy in patients with inflammatory bowel disease at increased risk of colon cancer. Gastrointest Endosc. 2019. PMID: 31009609. doi:10.1016/j.gie.2019.04.219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。